Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the FirmIf you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLNEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL) investors concerning the Company’s possible violations of the federal securities laws.
Replimune Group Inc. (REPL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationLaw Offices of Howard G. Smith announces an investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL) investors concerning the Company’s possible violations of federal securities laws.
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzThe Law Offices of Frank R. Cruz announces an investigation of Replimune Group Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate UpdateWOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingWOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (
NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting.
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingWOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (
NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting.
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDAWOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (
NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following collaborative communications with the U.S. Food and Drug Administration (FDA), the Company and the FDA have aligned on a path forward for resubmission and reconsideration of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLNEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law FirmLOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or “the Company”) (
NASDAQ: REPL) for violations of the securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPLNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLNEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingWOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (
NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaWOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (
NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma.
Replimune to Present at Two Upcoming Investor ConferencesWOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
Replimune to Present at the 44th Annual J.P. Morgan Healthcare ConferenceWOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate UpdateWOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update.
